Lumipulse® G HBcrAg

1. 临床意义:

HBcrAg是一种新型慢性乙肝血液标志物,它由乙型肝炎病毒前C/C区基因表达的几种抗原共同组成,包括HBcAg、HBeAg和前C22前体蛋白(p22cr)。

HBcrAg与肝组织内的cccDNA显著相关,可作为肝内HBV cccDNA的代替标志物, 反映肝内病毒复制状态。当使用NA治疗后,HBV DNA显著下降或消失时,HBcrAg仍然与cccDNA保持良好的相关性,反映实际的病毒状况。

  1. HBcrAg可预测停药后风险,辅助NA停药,是解决目前停药困难的新方案。
  2. HBcrAg 可预测抗病毒治疗患者的应答,监测治疗效果,协助医生选择最佳治疗方式。
  3. HBcrAg 可预测长期肝癌发生风险。
  4. HBcrAg 可检测出隐匿性肝炎。

2. 产品特色:

  1. 富士瑞必欧全球独家产品
  2. 简便、稳定、抗干扰
  3. 拥有专利技术

 

Lumipulse® G HBcrAg

产品编号 RUO

  •  
     

     

    参考文献

    Ma, H. et al. (2016) ‘HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon Alfa-2b’, Chinese Medical Journal, 129(18), pp. 2212–2219

    Mak, L. Y. et al. (2018) ‘Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection’, Alimentary Pharmacology and Therapeutics, 47(1), pp. 43–54. doi: 10.1111/apt.14376.

    Seto, W. K. et al. (2016) ‘Association of Hepatitis B Core-Related Antigen with Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy’, American Journal of Gastroenterology, 111(12), pp. 1788–1795

    Tanaka, E. and Matsumoto, A. (2014) ‘Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B’, Hepatology Research, 44(1), pp. 1–8

    Tseng, T. C. et al. (2019) ‘High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load’, Gastroenterology. The American Gastroenterological Association, 157(6), pp. 1518-1529

    Wang, B. et al. (2018) ‘HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues’, Journal of Viral Hepatitis, 25(8), pp. 886–893

  • 联系方式

    瑞必欧(上海)诊断技术有限公司

    中国上海市长宁区红宝路188号古北SOHO A座3302室
    上海
    201103
    中国

    021-62787686